Basal Cell Cancer
6
1
1
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
20%
1 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (6)
Using MC1R Genotype to Impact Melanoma Risk Behavior
R-5780-01 In Combination With PD-1 Checkpoint Inhibitors (Checkpoint Protein on Immune Cells Called T Cells) in Patients With Solid Tumors
Dose-Modulated Sonidegib Therapy for Periocular Basal Cell Carcinoma
How Consistent is the Output of DERM, When Used to Assess Images of Potentially Cancerous Skin Lesions.
Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma
Investigating the Effects of Orienting Skin Grafts Parallel to Skin Tension Lines on Quality of Life in Head and Neck Located Basal Cell Carcinoma